Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
Lymphoma patients treated with B-cell-depleting anti-CD20 monoclonal antibodies, such as rituximab or obinutuzumab, may have worse outcomes from COVID-19 infection, according to a study from France.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | COVID-19 | France Health | Health | Hematology | Lymphoma | Rituxan | Study